FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4300281978> ?p ?o ?g. }

• W4300281978 endingPage "777" @default.
• W4300281978 startingPage "777" @default.
• W4300281978 abstract "The epidermal growth factor receptor (EGFR) is a validated therapeutic target in many human cancers. In spite of the frequent EGFR overexpression in squamous cell carcinoma (SCC), the anti-EGFR antibody, cetuximab, as a single agent exhibits marginal efficacy. Our study shows an impressive efficacy of cetuximab/namitecan combination, which reflects a complete abrogation of EGFR expression, in SCC preclinical models characterized by high EGFR gene copy number. The study provides a molecular basis for a rational combination to be exploited for possible therapeutic applications in the clinical setting and suggests EGFR gene copy number as a possible marker for patient selection.Shortened constitutional telomere length is a well-established risk factor for the development of primary malignancies, related to genomic instability that may result from excessive telomere shortening. However, the relationship between telomere length and risk for second malignancies has not been explored. Gramatges and colleagues performed a matched case-control analysis of telomere length between survivors with and without second malignancies within the Childhood Cancer Survivor Study. A relationship was observed with shortened telomeres, driven by a highly significant association with thyroid second cancers. These results suggest cancer predisposition related to genetic or therapy-related telomere shortening, or other factors affecting telomere homeostasis.Both protein kinase C (PKC) and Twist1 play an important role in cancer pathology, including epithelial-mesenchymal transition as well as treatment resistance. Shiota and colleagues have explored the signaling pathway evoked by androgen-deprivation therapy (ADT) for prostate cancer. ADT induced PKC activation and Twist1 induction. On the other hand, an inhibition of PKC, especially PKCβ and PKCϵ, suppressed Twist1 expression, indicating the novel relationship between PKC and Twist1. Accordingly, PKC inhibition combined with ADT such as novel antiandrogen enzalutamide exerted excellent synergistic anticancer effects, suggesting that PKC inhibition as an alternative of Twist1 inhibition might be a promising therapeutic strategy.The uptake transporter SLC22A1 (OCT1) has been suggested to contribute to imatinib resistance; however, its role for imatinib transport into cells is controversial. Nies and colleagues applied an array of in vitro and in vivo model systems to systematically elucidate the contribution of OCT1 to imatinib transport. Using various OCT1-overexpressing cells, leukemic cells being devoid of OCT1 mRNA and protein, and Oct1-deficient mice the authors demonstrate that cellular uptake of imatinib is independent of OCT1. Therefore, OCT1 is apparently not a valid biomarker for imatinib resistance." @default.
• W4300281978 created "2022-10-03" @default.
• W4300281978 date "2014-02-15" @default.
• W4300281978 modified "2023-10-14" @default.
• W4300281978 title "Highlights of This Issue" @default.
• W4300281978 doi "https://doi.org/10.1158/1078-0432.777.20.4" @default.
• W4300281978 hasPublicationYear "2014" @default.
• W4300281978 type Work @default.
• W4300281978 citedByCount "0" @default.
• W4300281978 crossrefType "journal-article" @default.
• W4300281978 hasBestOaLocation W43002819781 @default.
• W4300281978 hasConcept C104317684 @default.
• W4300281978 hasConcept C121608353 @default.
• W4300281978 hasConcept C126322002 @default.
• W4300281978 hasConcept C143998085 @default.
• W4300281978 hasConcept C177336024 @default.
• W4300281978 hasConcept C2779438470 @default.
• W4300281978 hasConcept C2779998722 @default.
• W4300281978 hasConcept C2780192828 @default.
• W4300281978 hasConcept C502942594 @default.
• W4300281978 hasConcept C526805850 @default.
• W4300281978 hasConcept C54355233 @default.
• W4300281978 hasConcept C60644358 @default.
• W4300281978 hasConcept C71924100 @default.
• W4300281978 hasConcept C86803240 @default.
• W4300281978 hasConceptScore W4300281978C104317684 @default.
• W4300281978 hasConceptScore W4300281978C121608353 @default.
• W4300281978 hasConceptScore W4300281978C126322002 @default.
• W4300281978 hasConceptScore W4300281978C143998085 @default.
• W4300281978 hasConceptScore W4300281978C177336024 @default.
• W4300281978 hasConceptScore W4300281978C2779438470 @default.
• W4300281978 hasConceptScore W4300281978C2779998722 @default.
• W4300281978 hasConceptScore W4300281978C2780192828 @default.
• W4300281978 hasConceptScore W4300281978C502942594 @default.
• W4300281978 hasConceptScore W4300281978C526805850 @default.
• W4300281978 hasConceptScore W4300281978C54355233 @default.
• W4300281978 hasConceptScore W4300281978C60644358 @default.
• W4300281978 hasConceptScore W4300281978C71924100 @default.
• W4300281978 hasConceptScore W4300281978C86803240 @default.
• W4300281978 hasIssue "4" @default.
• W4300281978 hasLocation W43002819781 @default.
• W4300281978 hasOpenAccess W4300281978 @default.
• W4300281978 hasPrimaryLocation W43002819781 @default.
• W4300281978 hasRelatedWork W1969669354 @default.
• W4300281978 hasRelatedWork W1977855150 @default.
• W4300281978 hasRelatedWork W1995828194 @default.
• W4300281978 hasRelatedWork W2000204434 @default.
• W4300281978 hasRelatedWork W2016492905 @default.
• W4300281978 hasRelatedWork W2023373067 @default.
• W4300281978 hasRelatedWork W2053404193 @default.
• W4300281978 hasRelatedWork W2054822224 @default.
• W4300281978 hasRelatedWork W2277378171 @default.
• W4300281978 hasRelatedWork W4234363737 @default.
• W4300281978 hasVolume "20" @default.
• W4300281978 isParatext "false" @default.
• W4300281978 isRetracted "false" @default.
• W4300281978 workType "article" @default.